This is the authors' abstract. We don't add key points for this paper.
This paper examines the transformative impact of artificial intelligence (AI) on pharmacogenomics, signaling a paradigm shift in personalized medicine. With a focus on enhancing drug response prediction and treatment optimization, AI, particularly machine learning and deep learning algorithms, navigates the complexity of genomic data. By elucidating intricate relationships between genetic factors and drug responses, AI augments the identification of genetic markers and contributes to the development of comprehensive models. The review emphasizes AI's role in guiding treatment decisions, minimizing adverse reactions, and optimizing drug dosages in clinical settings. Ethical considerations, challenges, and future directions are also discussed. This work underscores the synergy of AI and pharmacogenomics, offering a more effective and patient-centric approach to drug therapy, marking a significant advancement in the field of personalized medicine.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Taherdoost et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: